Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report details a case of a 43-year-old woman developing yellowish papular eruptions alongside typical acneiform skin reactions on her cheeks and chest following a switch from cetuximab to panitumumab treatment.

This article discusses the common cutaneous side effects associated with EGFR inhibitors, emphasizing the importance of their management due to potential impacts on patients' quality of life and therapy response; no new empirical findings are reported.

This study found that histopathologic features of erythematous papulopustular eruption due to EGFR inhibitors vary with eruption severity and differ between cetuximab and erlotinib treatments.

In this study, researchers found that disrupting EGFR signaling in mice led to increased inflammation and hair follicle damage but that inhibiting the JAK-STAT1 pathway could restore hair growth and skin function.

This study observed that trichoscopic changes associated with EGFRI treatment include pili torti and asymmetric hyperpigmented fusiform widening, along with dermoscopic skin manifestations such as scale and branching vessels.

This study describes a case of erlotinib-induced alopecia, unresponsive to traditional corticosteroid treatments, that was successfully managed with doxycycline, suggesting a novel approach for EGFR inhibitor-associated alopecia.

This article discusses common skin side effects of EGFR inhibitors like cetuximab, noting their management remains based on clinical experience without strict therapy protocols, but provides no new clinical findings.

This study found that treatment with EGFR inhibitors or mitogen-activated kinase inhibitors may compromise the immune privilege of human scalp hair follicles, suggesting new directions for managing drug-induced folliculitis.

This study identified a novel microscopic "arrow sign" in hair root sheaths of patients on EGFR inhibitors, potentially aiding in diagnosing related hair changes and differentiating from fungal infections.

This report discusses two cases where patients continued EGFR inhibitor therapy while receiving topical treatments for SDRIFE, highlighting the importance of dermatologists in managing such cutaneous adverse events without stopping cancer treatment.

This study found that lasers and light devices may alleviate recalcitrant skin side effects in cancer patients treated with EGFR inhibitors, offering an alternative for those who do not respond to traditional therapies.

This mini review reports on papulopustular eruptions linked to classical EGFR inhibitors, MEK inhibitors, and amivantamab, highlighting distinct dermatologic toxicities in each treatment context and exploring underlying mechanisms and management strategies.

This review found that adding immune checkpoint inhibitors to cancer treatment regimens likely increases the incidence of specific drug-related skin toxicities in adult Asian patients, highlighting the need for careful monitoring and management strategies.

This review highlights that chemotherapy-induced skin toxicities from EGFR inhibitors in breast cancer treatment can significantly impact patient quality of life and treatment adherence, emphasizing the importance of proactive management and patient discussions.

This study found that in mice, hyper-activated JAK-STAT1 signaling due to EGFR inhibitor treatment leads to scarring alopecia, but JAK1/2 inhibition can restore hair follicle immune privilege and promote new hair growth.

This study found that epidermal growth factor receptor inhibitors used in cancer treatment induce a distinct inflammatory response in hair follicles, marked by immune privilege collapse and upregulation of inflammatory pathways.

This study using a genetic mouse model found that S. aureus-driven dysbiosis sustains inflammatory skin side effects from EGFR inhibitors, suggesting prophylactic antibiotic treatment may reduce rash severity without fixing barrier defects.

This study demonstrated that disrupting EGFR signaling in mice leads to immune sensitivity compromising the hair follicle's protective environment, but JAK1/2 inhibition can restore this immune privilege and stimulate hair growth, suggesting a potential therapy for scarring hair loss diseases like cicatricial alopecia.

In this reported case, a 50-year-old man developed an acneiform rash, a common skin side effect of EGFR inhibitor therapy, after starting lapatinib for breast cancer; treatment with doxycycline and hydrocortisone cream led to significant improvement within one week.

This report describes a rare case of eyelash overgrowth and eyelid irritation in a woman treated with erlotinib for lung adenocarcinoma, highlighting a potential side effect of the drug.

This article discusses the cutaneous side effects of erlotinib, an EGFR inhibitor, in a patient with non-small cell lung cancer, reporting nonscarring alopecia and indicative scalp biopsy findings.

This source reviews the common skin-related side effects of tyrosine kinase inhibitors in treating endocrine cancers and emphasizes that proactive, multidisciplinary management can effectively control these adverse events without compromising cancer treatment efficacy.

This review summarizes adverse events associated with EGFR-targeting cancer therapies, such as skin rashes and lung disease, and reports no new clinical results.

In this report, two cases of non-small cell lung cancer treated with gefitinib showed unexpected hair growth, suggesting a potential new application of EGFR-TKIs for alopecia.

In this study, researchers found that applying topical aprepitant, which blocks substance P receptors, significantly reduced facial dermatitis and hair loss in rats experiencing erlotinib-induced skin side effects, highlighting the neurogenic inflammation's role and the protective effect of ROS inhibition.

This study described the safety profile of tyrosine kinase inhibitors in treating various solid tumors, finding that the observed toxicities were consistent with existing literature.

This study mapped the safety profile of EGFR-TKIs by analyzing FDA adverse event reports, highlighting unexpected reactions like intestinal obstruction and hypokalaemia with gefitinib and erlotinib.

This study used in silico analysis to identify 4-[2-(4-nitrophenyl)ethylcarbamoyl]benzenesulfonyl as a potential inhibitor of the EGFR mutant associated with NSCLC, highlighting the need for further in vitro and in vivo validation.

This study examined the FDA Adverse Events Reporting System and found new dermatologic adverse events associated with EGFR-TKIs in non-small cell lung cancer patients, such as specific skin, nail, and hair issues, that aren't currently listed on drug labels.

This study found that CI-1033 caused skin lesions in rats that resemble effects seen in humans receiving EGF receptor inhibitors, suggesting this animal model can help explore the mechanisms behind this cutaneous toxicity.